Regeneron Pharmaceuticals (NASDAQ:REGN) Given New $1,000.00 Price Target at Bernstein Bank

Regeneron Pharmaceuticals (NASDAQ:REGN) had its price objective decreased by Bernstein Bank from $1,070.00 to $1,000.00 in a research note released on Tuesday.

REGN has been the topic of several other reports. UBS Group cut Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and reduced their price objective for the stock from $1,130.00 to $738.00 in a research note on Thursday, January 16th. Canaccord Genuity Group started coverage on Regeneron Pharmaceuticals in a report on Tuesday, December 17th. They set a “hold” rating and a $165.00 price target on the stock. Piper Sandler dropped their price objective on shares of Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an “overweight” rating for the company in a research note on Monday, January 27th. Morgan Stanley reduced their target price on shares of Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an “overweight” rating on the stock in a research note on Friday, November 1st. Finally, Truist Financial dropped their price target on shares of Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a “buy” rating for the company in a research note on Wednesday, January 8th. One research analyst has rated the stock with a sell rating, seven have given a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $983.65.

Regeneron Pharmaceuticals Stock Up 4.5 %

Shares of REGN opened at $697.05 on Tuesday. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.28 and a quick ratio of 4.46. The stock has a market capitalization of $76.60 billion, a price-to-earnings ratio of 17.25, a price-to-earnings-growth ratio of 1.60 and a beta of 0.08. Regeneron Pharmaceuticals has a 1 year low of $642.00 and a 1 year high of $1,211.20. The business’s 50 day simple moving average is $719.16 and its 200-day simple moving average is $918.90.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, beating the consensus estimate of $11.21 by $0.86. Regeneron Pharmaceuticals had a net margin of 33.61% and a return on equity of 16.88%. The business had revenue of $3.79 billion during the quarter, compared to analyst estimates of $3.76 billion. During the same quarter last year, the business earned $11.86 earnings per share. Regeneron Pharmaceuticals’s quarterly revenue was up 10.3% compared to the same quarter last year. As a group, equities analysts expect that Regeneron Pharmaceuticals will post 37.75 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, March 20th. Stockholders of record on Thursday, February 20th will be paid a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.50%.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

Large investors have recently bought and sold shares of the business. Rakuten Securities Inc. increased its holdings in shares of Regeneron Pharmaceuticals by 380.0% in the 3rd quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 19 shares during the period. FSA Wealth Management LLC purchased a new stake in shares of Regeneron Pharmaceuticals during the 3rd quarter worth $26,000. Fairfield Financial Advisors LTD bought a new stake in Regeneron Pharmaceuticals during the third quarter valued at about $37,000. Truvestments Capital LLC purchased a new position in Regeneron Pharmaceuticals in the third quarter valued at about $39,000. Finally, Valley Wealth Managers Inc. purchased a new stake in shares of Regeneron Pharmaceuticals during the third quarter valued at about $49,000. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.